• Emgality maker Lilly courts payers with new migraine ER data fiercepharma
    July 13, 2019
    Sales of Eli Lilly’s migraine and cluster headache med Emgality have lagged behind competitors from Amgen and Novartis and Teva Pharmaceutical. And in its push to bring payers on board, Lilly is deploying a full-court press with some new patient data.
PharmaSources Customer Service